|
gptkbp:instanceOf
|
opioid
|
|
gptkbp:approvedBy
|
1953
|
|
gptkbp:ATCCode
|
gptkb:N02AA02
|
|
gptkbp:brand
|
gptkb:Levo-Dromoran
|
|
gptkbp:CASNumber
|
77-07-6
|
|
gptkbp:chemicalFormula
|
C17H23NO
|
|
gptkbp:contraindication
|
respiratory depression
acute asthma
paralytic ileus
|
|
gptkbp:developedBy
|
gptkb:Hoffmann-La_Roche
|
|
gptkbp:eliminationHalfLife
|
11-16 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:hasInChIKey
|
QNOFZBVKZBICQO-UHFFFAOYSA-N
|
|
gptkbp:hasSMILES
|
CN1CCC23C4CCC2C1CC(O)C4CC3
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
levorphanol
|
|
gptkbp:isomerOf
|
gptkb:dextrorphan
|
|
gptkbp:IUPACName
|
(−)-3-hydroxy-N-methylmorphinan
|
|
gptkbp:legalStatus
|
gptkb:Schedule_II_controlled_substance
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
253.37 g/mol
|
|
gptkbp:pregnancyCategory
|
C
|
|
gptkbp:proteinBinding
|
40%
|
|
gptkbp:PubChem_CID
|
CHEMBL1201207
4515032
5361806
DB00854
|
|
gptkbp:relatedTo
|
gptkb:morphine
gptkb:oxymorphone
gptkb:naloxone
|
|
gptkbp:riskFactor
|
addiction
abuse
dependence
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
subcutaneous
intravenous
|
|
gptkbp:sideEffect
|
nausea
constipation
dizziness
drowsiness
respiratory depression
|
|
gptkbp:target
|
gptkb:delta-opioid_receptor
gptkb:kappa-opioid_receptor
gptkb:mu-opioid_receptor
NMDA receptor antagonist
|
|
gptkbp:UNII
|
7D3A2DKC3S
|
|
gptkbp:usedFor
|
moderate to severe pain
|
|
gptkbp:bfsParent
|
gptkb:dextromethorphan
gptkb:opioid
|
|
gptkbp:bfsLayer
|
6
|